Mar 14, 2023 / 01:00PM GMT
Steven James Valiquette - Barclays Bank PLC, Research Division - Research Analyst
I'm Steve Valiquette, the health care services analyst here at Barclays. Welcome to our next session with Centene. With us from the company, we have Sarah London, company's CEO; and also Drew Asher, CFO, as well; and Jen Gilligan from IR in the audience here. So this will be a fireside chat. So I guess with that, we'll just kick right off here. Welcome, first of all.
Sarah M. London - Centene Corporation - CEO & Director
Thank you.
Questions and Answers:
Steven James Valiquette - Barclays Bank PLC, Research Division - Research AnalystAll right. Great. So I guess just starting around the redeterminations. Obviously, that's going to be top of mind for a lot of investors right now. And also, I think, some debate around the overall MLR impact related to redeterminations. I think on the one hand, you have some members enrolled in commercial exchange plans typically generate higher PMPMs and Medicaid members. There's also some